{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:09:16Z","timestamp":1792739356021,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T00:00:00Z","timestamp":1376697600000},"content-version":"vor","delay-in-days":442,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuron"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.neuron.2012.05.009","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T15:18:41Z","timestamp":1340205521000},"page":"1031-1044","source":"Crossref","is-referenced-by-count":720,"title":["Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis"],"prefix":"10.1016","volume":"74","author":[{"given":"Holly\u00a0B.","family":"Kordasiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa\u00a0M.","family":"Stanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward\u00a0V.","family":"Wancewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa\u00a0M.","family":"McAlonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly\u00a0A.","family":"Pytel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan\u00a0W.","family":"Artates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng\u00a0H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamya\u00a0S.","family":"Shihabuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.\u00a0Frank","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don\u00a0W.","family":"Cleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuron.2012.05.009_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuron.2012.05.009_bib2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1126\/science.1123511","article-title":"Onset and progression in inherited ALS determined by motor neurons and microglia","volume":"312","author":"Boill\u00e9e","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.neuron.2012.05.009_bib3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuron.2012.05.009_bib4","first-page":"103","article-title":"Using antibodies to analyze polyglutamine stretches","volume":"277","author":"Brooks","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.neuron.2012.05.009_bib5","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuron.2012.05.009_bib6","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1742-4658.2009.06908.x","article-title":"Ribonuclease H: the enzymes in eukaryotes","volume":"276","author":"Cerritelli","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.neuron.2012.05.009_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1081\/NCN-120022050","article-title":"Solid phase synthesis of phosphorothioate oligonucleotides utilizing diethyldithiocarbonate disulfide (DDD) as an efficient sulfur transfer reagent","volume":"22","author":"Cheruvallath","year":"2003","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.neuron.2012.05.009_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0167-4781(99)00148-7","article-title":"Molecular mechanisms of action of antisense drugs","volume":"1489","author":"Crooke","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuron.2012.05.009_bib9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00005072-198809000-00003","article-title":"Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease","volume":"47","author":"de la Monte","year":"1988","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuron.2012.05.009_bib10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.nbd.2007.11.003","article-title":"Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in\u00a0vivo","volume":"29","author":"Denovan-Wright","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuron.2012.05.009_bib11","doi-asserted-by":"crossref","first-page":"9773","DOI":"10.1523\/JNEUROSCI.3183-05.2005","article-title":"Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease","volume":"25","author":"D\u00edaz-Hern\u00e1ndez","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuron.2012.05.009_bib12","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2012.05.009_bib13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","article-title":"Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice","volume":"26","author":"Dragatsis","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuron.2012.05.009_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2012.05.009_bib15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2008.50","article-title":"AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease","volume":"16","author":"Franich","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuron.2012.05.009_bib16","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","article-title":"Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat","volume":"49","author":"Gagnon","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuron.2012.05.009_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","article-title":"Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules","volume":"118","author":"Gauthier","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.neuron.2012.05.009_bib18","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuron.2012.05.009_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1326-2-8","article-title":"Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease","volume":"2","author":"Gu","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuron.2012.05.009_bib20","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2012.05.009_bib21","first-page":"1444","article-title":"Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?","volume":"2","author":"Henry","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.neuron.2012.05.009_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"Hodgson","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.neuron.2012.05.009_bib23","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/hmg\/2.12.2069","article-title":"Characterization and localization of the Huntington disease gene product","volume":"2","author":"Hoogeveen","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuron.2012.05.009_bib24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuron.2012.05.009_bib25","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.neuron.2012.05.009_bib26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nmeth.1261","article-title":"Linking SNPs to CAG repeat length in Huntington's disease patients","volume":"5","author":"Liu","year":"2008","journal-title":"Nat. Methods"},{"key":"10.1016\/j.neuron.2012.05.009_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2006.02.141","article-title":"rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse","volume":"343","author":"Machida","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuron.2012.05.009_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.neuron.2012.05.009_bib29","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2012.05.009_bib30","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuron.2012.05.009_bib31","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1074\/jbc.274.3.1715","article-title":"Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression","volume":"274","author":"McKay","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuron.2012.05.009_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1389450053344975","article-title":"Huntington's disease: new frontiers for molecular and cell therapy","volume":"6","author":"Melone","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuron.2012.05.009_bib33","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.neuron.2012.05.009_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2012.01.034","article-title":"Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure","author":"Peters-Libeu","year":"2012","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.neuron.2012.05.009_bib35","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr. Biol."},{"key":"10.1016\/j.neuron.2012.05.009_bib36","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","article-title":"Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington's disease transgenic mice","volume":"12","author":"Rodriguez-Lebron","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuron.2012.05.009_bib37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.58.5.695","article-title":"Regional and progressive thinning of the cortical ribbon in Huntington's disease","volume":"58","author":"Rosas","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2012.05.009_bib38","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/mds.20979","article-title":"Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures","volume":"21","author":"Rosas","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2012.05.009_bib39","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/awn025","article-title":"Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity","volume":"131","author":"Rosas","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2012.05.009_bib40","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuron.2012.05.009_bib41","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/hmg\/ddl072","article-title":"Body weight is modulated by levels of full-length huntingtin","volume":"15","author":"Van Raamsdonk","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuron.2012.05.009_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","article-title":"Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA","volume":"53","author":"Wang","year":"2005","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuron.2012.05.009_bib43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ng1297-404","article-title":"Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion","volume":"17","author":"White","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuron.2012.05.009_bib44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/abio.1999.4085","article-title":"Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in\u00a0vitro","volume":"270","author":"Winer","year":"1999","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.neuron.2012.05.009_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.neuron.2012.05.009_bib46","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-3565(24)38750-6","article-title":"Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice","volume":"296","author":"Yu","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuron.2012.05.009_bib47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jps.10473","article-title":"Tissue disposition of 2\u2032-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys","volume":"93","author":"Yu","year":"2004","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.neuron.2012.05.009_bib48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuron.2012.05.009_bib49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ng1219","article-title":"Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes","volume":"35","author":"Zuccato","year":"2003","journal-title":"Nat. Genet."}],"container-title":["Neuron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627312004448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627312004448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T08:30:05Z","timestamp":1743582605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896627312004448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0896627312004448"],"URL":"https:\/\/doi.org\/10.1016\/j.neuron.2012.05.009","relation":{},"ISSN":["0896-6273"],"issn-type":[{"value":"0896-6273","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}